Klaus is a founding and managing partner of Pureos and has been a venture capital investor since 2001, involved with life science companies across different regions, stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Bio-pharmaceutical companies that Klaus has invested in include AM-Pharma, Alpex Pharma, Cadence Pharmaceuticals, Glycart Biotechnology, Hummingbird Bioscience, ImCheck Therapeutics and Vaximm. Prior to venture capital, Klaus was a researcher at ETH Zurich and a business consultant at Booz Allen & Hamilton. Klaus holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in molecular biology from the University of Heidelberg (ZMBH).
Klaus Breiner
Board Member